Technology
Health
Biotechnology

Conatus

$1.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.08 (-6.25%) Today
+$0.05 (4.17%) After Hours

Why Robinhood?

You can buy or sell Conatus and other stocks, options, ETFs, and crypto commission-free!

About

Conatus Pharmaceuticals Inc. Common Stock, also called Conatus, is a biotechnology company, which engages in the development and commercialization of medicines for the treatment of liver diseases. Read More It focuses in development of emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease, which reduce the activities of human caspases. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.

Employees
31
Headquarters
San Diego, California
Founded
2005
Market Cap
42.45M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
726.83K
High Today
$1.28
Low Today
$1.18
Open Price
$1.27
Volume
1.04M
52 Week High
$6.74
52 Week Low
$1.15

Collections

Technology
Health
Biotechnology
2013 IPO
US
North America

News

Yahoo FinanceMar 22

Conatus (CNAT) Declines on Failure of NASH Fibrosis Study

Shares of Conatus Pharmaceuticals Inc. CNAT plunged 50.8% in after-hours trading, after it announced disappointing top-line results from the phase IIb ENCORE-NF study. Notably, shares of Conatus have plummeted 55.2% in the past six months compared with the industry’s decline of 4.7%. Conatus is conducting three phase IIb ENCORE studies on emricasan for treating fibrosis or cirrhosis induced by nonalcoholic steatohepatitis (NASH). The programs are named ENCORE-NF (for NASH fibrosis), ENCORE-PH (for portal ...

356
BenzingaMar 22

Conatus (NASDAQ:CNAT) Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo

Shares of microcap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate.

598
Markets InsiderMar 21

Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis

SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis. The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72. “Although emricasan did not have the desired effect in these earlier-stage NASH fibrosis patients, we beli...

962

Earnings

-$0.20
-$0.15
-$0.10
-$0.05
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 1, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.